| Effect of supplemental lutein and zeaxanthin on serum, macular pigmentation, and visual performance in patients with early age-related macular degeneration 2015 · 10 mg lutein · Adults aged over 50 with clinically diagnosed early age-related macular degeneration | 10 mg | 2 years | 28 |
| Effect of supplemental lutein and zeaxanthin on serum, macular pigmentation, and visual performance in patients with early age-related macular degeneration 2015 · 20 mg lutein · Adults aged over 50 with clinically diagnosed early age-related macular degeneration | 20 mg | 2 years | 28 |
| Improvement of retinal function in early age-related macular degeneration after lutein and zeaxanthin supplementation: a randomized, double-masked, placebo-controlled trial 2012 · 10 mg/d lutein · People with early age-related macular degeneration; age range and sex not reported | 10 mg | 48 weeks | 27 |
| Improvement of retinal function in early age-related macular degeneration after lutein and zeaxanthin supplementation: a randomized, double-masked, placebo-controlled trial 2012 · 20 mg/d lutein · People with early age-related macular degeneration; age range and sex not reported | 20 mg | 48 weeks | 27 |
| A 12-week lutein supplementation improves visual function in Chinese people with long-term computer display light exposure 2009 · Group L12 · Healthy adults aged 22–30 years with long-term computer display light exposure | 12 mg | 12 weeks | 13 |
| Cognitive findings of an exploratory trial of docosahexaenoic acid and lutein supplementation in older women 2008 · Lutein · Women aged 60–80 years without stated cognitive impairment | 12 mg | 120 days | 11 |
| Lutein supplementation improves visual performance in Chinese drivers: 1-year randomized, double-blind, placebo-controlled study 2013 · active (A) group · healthy drivers with long-term light exposure | 20 mg | 1 year | — |
| Effect of lutein supplementation on visual function in nonproliferative diabetic retinopathy 2017 · lutein group · Patients with nonproliferative diabetic retinopathy; age and sex not stated | 10 mg | 36 weeks | — |
| Lutein supplementation combined with a low-calorie diet in middle-aged obese individuals: effects on anthropometric indices, body composition and metabolic parameters 2021 · lutein group · Adults aged 45–65 years with obesity, following a low-calorie diet | 20 mg | 10 weeks | — |
| A 12-week lutein supplementation improves visual function in Chinese people with long-term computer display light exposure 2009 · Group L6 · Healthy adults aged 22–30 years with long-term computer display light exposure | 6 mg | 12 weeks | 12 |
| Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial 2013 · lutein + zeaxanthin group · Adults aged 50 to 85 years at risk for progression to advanced age-related macular degeneration, with bilateral large drusen or large drusen in one eye and advanced AMD in the fellow eye | 10 mg | 5 years | — |
| Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3 2014 · lutein/zeaxanthin · Adults with high risk of progression to late age-related macular degeneration; mean age 73.1 years; sex not specified | 10 mg | 1789 days | — |
| No CFH or ARMS2 Interaction with Omega-3 Fatty Acids, Low versus High Zinc, or β-Carotene versus Lutein and Zeaxanthin on Progression of Age-Related Macular Degeneration in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report No. 18 2019 · Lutein and zeaxanthin addition · Adults with bilateral large drusen or late AMD in one eye and large drusen in the fellow eye | 10 mg | 5 years | — |
| Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial 2013 · lutein + zeaxanthin and DHA + EPA group · Adults aged 50 to 85 years at risk for progression to advanced age-related macular degeneration, with bilateral large drusen or large drusen in one eye and advanced AMD in the fellow eye | 10 mg | 5 years | — |
| Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3 2014 · lutein/zeaxanthin and DHA/EPA · Adults with high risk of progression to late age-related macular degeneration; mean age 73.1 years; sex not specified | 10 mg | 1789 days | — |
| No CFH or ARMS2 Interaction with Omega-3 Fatty Acids, Low versus High Zinc, or β-Carotene versus Lutein and Zeaxanthin on Progression of Age-Related Macular Degeneration in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report No. 18 2019 · Lutein and zeaxanthin plus omega-3 fatty acids · Adults with bilateral large drusen or late AMD in one eye and large drusen in the fellow eye | 10 mg | 5 years | — |
| Supplemental Retinal Carotenoids Enhance Memory in Healthy Individuals with Low Levels of Macular Pigment in A Randomized, Double-Blind, Placebo-Controlled Clinical Trial 2018 · active group · Healthy individuals with low macular pigment levels; mean age 45.42 years, 51.6% male | 10 mg | 1 year | 45 |
| Effects of a Lutein and Zeaxanthin Intervention on Cognitive Function: A Randomized, Double-Masked, Placebo-Controlled Trial of Younger Healthy Adults 2017 · active supplement group · Healthy adults aged 18–30 years, college students, without a stated diagnosed condition | 10 mg | 1 year | 37 |
| Effects of Astaxanthin, Lutein, and Zeaxanthin on Eye-Hand Coordination and Smooth-Pursuit Eye Movement after Visual Display Terminal Operation in Healthy Subjects: A Randomized, Double-Blind Placebo-Controlled Intergroup Trial 2023 · active group · Healthy Japanese males and females aged 20–60 years who routinely used visual display terminals or played video games | 10 mg | 8 weeks | 32 |
| Effect of supplemental lutein and zeaxanthin on serum, macular pigmentation, and visual performance in patients with early age-related macular degeneration 2015 · lutein (10 mg) + zeaxanthin (10 mg) · Adults aged over 50 with clinically diagnosed early age-related macular degeneration | 10 mg | 2 years | 28 |
| Improvement of retinal function in early age-related macular degeneration after lutein and zeaxanthin supplementation: a randomized, double-masked, placebo-controlled trial 2012 · 10 mg/d lutein plus 10 mg/d zeaxanthin · People with early age-related macular degeneration; age range and sex not reported | 10 mg | 48 weeks | 27 |
| Increases in plasma lutein through supplementation are correlated with increases in physical activity and reductions in sedentary time in older adults 2014 · Lutein · Adults aged 55–80 who were not obese and did not meet physical activity guidelines | 21 mg | 4 weeks | 19 |
| Cognitive findings of an exploratory trial of docosahexaenoic acid and lutein supplementation in older women 2008 · Combination of DHA and lutein · Women aged 60–80 years without stated cognitive impairment | 12 mg | 120 days | 14 |
| Supplementation with beta-carotene or a similar amount of mixed carotenoids protects humans from UV-induced erythema 2003 · carotenoid mix · Volunteers with skin type II | 8 mg | 12 weeks | 12 |
| Clinical trial of lutein in patients with retinitis pigmentosa receiving vitamin A 2010 · lutein + A group · Adults with retinitis pigmentosa | 12 mg | 4 years | — |
| Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial 2015 · Lutein/zeaxanthin · Older adults with intermediate or late age-related macular degeneration; mean age about 73 years, both sexes | 10 mg | 5 years | — |
| Effects of lutein supplement on serum inflammatory cytokines, ApoE and lipid profiles in early atherosclerosis population 2013 · A+L · Adults with early atherosclerosis | 20 mg | 90 days | 34 |
| Effects of a lutein supplement on the plasma lutein concentration and macular pigment in patients with central serous chorioretinopathy 2014 · lutein group · Patients with central serous chorioretinopathy (age range and sex not stated) | 20 mg | 120 days | 20 |
| Lutein ester in serum after lutein supplementation in human subjects 1998 · lutein supplementation · Apparently healthy, non-smoking adults aged 25–45 years; nine men and nine women | 15 mg | 120 days | 18 |
| Randomized, Placebo-Controlled, Single-Blind Study of Lutein Supplementation on Carotenoid Status and Cognition in Persons with Multiple Sclerosis 2023 · treatment · Adults with relapsing-remitting multiple sclerosis | 20 mg | 120 days | 12 |
| Comparison of dietary supplementation with lutein diacetate and lutein: a pilot study of the effects on serum and macular pigment 2012 · Group 1 (lutein diacetate) · Study subjects; age, sex, and health condition are not reported. | 20 mg | 24 weeks | 10 |
| Comparison of dietary supplementation with lutein diacetate and lutein: a pilot study of the effects on serum and macular pigment 2012 · Group 2 (lutein) · Study subjects; age, sex, and health condition are not reported. | 20 mg | 24 weeks | 10 |
| Comparison of macular pigment and serum lutein concentration changes between free lutein and lutein esters supplements in Japanese subjects 2016 · free lutein group · Healthy Japanese adults aged 22–47 years | 10 mg | 90 days | 10 |
| Comparison of macular pigment and serum lutein concentration changes between free lutein and lutein esters supplements in Japanese subjects 2016 · lutein esters group · Healthy Japanese adults aged 22–47 years | 20 mg | 90 days | 10 |
| A European multicentre, placebo-controlled supplementation study with alpha-tocopherol, carotene-rich palm oil, lutein or lycopene: analysis of serum responses 2002 · Lutein from marigold extracts · Healthy men and women aged 25–45 years from five European regions | 15 mg | — | — |
| Dose-ranging study of lutein supplementation in persons aged 60 years or older 2006 · 10-mg lutein group · Adults aged 60 years or older, with no AMD, large drusen, or advanced AMD | 10 mg | 26 weeks | — |
| The influence of supplemental lutein and docosahexaenoic acid on serum, lipoproteins, and macular pigmentation 2008 · lutein · Women aged 60–80 years | 12 mg | 120 days | — |
| Serum lutein and its dynamic changes during supplementation with lutein in Chinese subjects 2009 · 12 mg lutein/d group · Healthy Chinese subjects; age and sex range not specified | 12 mg | 12 weeks | — |
| Serum lutein response is greater from free lutein than from esterified lutein during 4 weeks of supplementation in healthy adults 2010 · free lutein (fL) group · Adults aged 23–52 years with baseline serum lutein below 20 µg/dL and BMI above 20 and below 30 kg/m² | 12.2 mg | 4 weeks | — |
| Macular pigment density changes in Japanese individuals supplemented with lutein or zeaxanthin: quantification via resonance Raman spectrophotometry and autofluorescence imaging 2012 · Lutein group · Healthy Japanese volunteers; age range and sex distribution not specified | 10 mg | 90 days | — |
| Serum and macular responses to multiple xanthophyll supplements in patients with early age-related macular degeneration 2013 · low lutein (LL) · Chinese patients older than 50 years with early age-related macular degeneration | 10 mg | 48 weeks | — |
| Serum and macular responses to multiple xanthophyll supplements in patients with early age-related macular degeneration 2013 · high lutein (HL) · Chinese patients older than 50 years with early age-related macular degeneration | 20 mg | 48 weeks | — |
| Lutein supplementation reduces plasma lipid peroxidation and C-reactive protein in healthy nonsmokers 2013 · 10 mg/d lutein group · Healthy nonsmokers; age and sex not specified | 10 mg | 12 weeks | — |
| Lutein supplementation reduces plasma lipid peroxidation and C-reactive protein in healthy nonsmokers 2013 · 20 mg/d lutein group · Healthy nonsmokers; age and sex not specified | 20 mg | 12 weeks | — |
| Effects of Long-Chain Polyunsaturated Fatty Acids in Combination with Lutein and Zeaxanthin on Episodic Memory in Healthy Older Adults 2023 · LCPUFAs + LZ group, Trial 2 · Healthy Japanese adults aged 55–79 with memory complaints and no dementia; cognitive-decline subgroup had MoCA-J scores below 23 | 10 mg | 12 weeks | 96 |
| Enhanced physical and cognitive performance in active duty Airmen: evidence from a randomized multimodal physical fitness and nutritional intervention 2020 · exercise plus nutritional supplement group · Active-duty Air Force Airmen aged 18–45; no qualifying disease or deficiency was stated | 12 mg | 12 weeks | 70 |
| Effects of Long-Chain Polyunsaturated Fatty Acids in Combination with Lutein and Zeaxanthin on Episodic Memory in Healthy Older Adults 2023 · LCPUFAs + LZ group, Trial 1 · Healthy Japanese adults aged 55–79 with memory complaints and no dementia; cognitive-decline subgroup had MoCA-J scores below 23 | 10 mg | 24 weeks | 40 |
| TOZAL Study: an open case control study of an oral antioxidant and omega-3 supplement for dry AMD 2007 · Sham MCS and nutritional supplement · Adults aged 50–90 with dry age-related macular degeneration in at least one eye | 8 mg | 24 weeks | 37 |
| Omega-3 fatty acid, carotenoid and vitamin E supplementation improves working memory in older adults: A randomised clinical trial 2022 · active group · Cognitively healthy adults aged 65 years and older | 10 mg | 2 years | 30 |
| Visual Function and Macular Carotenoid Changes in Eyes with Retinal Drusen-An Open Label Randomized Controlled Trial to Compare a Micronized Lipid-Based Carotenoid Liquid Supplementation and AREDS-2 Formula 2020 · LM group · Adults aged 54–80 with retinal drusen and risk of age-related macular degeneration | 15 mg | 26 weeks | 29 |
| Visual Function and Macular Carotenoid Changes in Eyes with Retinal Drusen-An Open Label Randomized Controlled Trial to Compare a Micronized Lipid-Based Carotenoid Liquid Supplementation and AREDS-2 Formula 2020 · PV group · Adults aged 54–80 with retinal drusen and risk of age-related macular degeneration | 10 mg | 26 weeks | 20 |
| Consumption of Nutritionally Enriched Hen Eggs Enhances Endothelium-Dependent Vasodilation via Cyclooxygenase Metabolites in Healthy Young People-A Randomized Study 2023 · Nutri4 (enriched eggs) · Healthy young adults aged 18–30 years, both sexes, with normal blood pressure and BMI | 1.85 mg | 3 weeks | 20 |
| Carotenoids and antioxidants in age-related maculopathy italian study: multifocal electroretinogram modifications after 1 year 2008 · treated AMD (T-AMD) group · Patients with nonadvanced age-related macular degeneration; mean age 69.4 years | 10 mg | 1 year | 15 |
| Effects of Macuprev(®) Supplementation in Age-Related Macular Degeneration: A Double-Blind Randomized Morpho-Functional Study Along 6 Months of Follow-Up 2019 · AMD-M group · Adults with intermediate age-related macular degeneration; 9 male and 21 female enrolled overall, mean age 69.32 years | 20 mg | 26 weeks | 15 |
| Beneficial Effects of Micronutrient Supplementation in Restoring the Altered Microbiota and Gut-Retina Axis in Patients with Neovascular Age-Related Macular Degeneration-A Randomized Clinical Trial 2024 · intervention group · Adults with neovascular age-related macular degeneration; mean age 77.8 years | 10 mg | 26 weeks | 15 |
| Effects of dietary supplementation with a combination of fish oil, bilberry extract, and lutein on subjective symptoms of asthenopia in humans 2011 · Active group · People with subjective symptoms of asthenopia; age and sex not reported | 17.5 mg | 4 weeks | 11 |
| Carotenoids in Age-related Maculopathy Italian Study (CARMIS): two-year results of a randomized study 2012 · treated group · Patients with age-related macular degeneration; age and sex not stated | 10 mg | 2 years | — |
| Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial 2015 · DHA/EPA and lutein/zeaxanthin · Older adults with intermediate or late age-related macular degeneration; mean age about 73 years, both sexes | 10 mg | 5 years | — |
| Effect of Dietary Supplementation with Lutein, Zeaxanthin, and Elderberries on Dry Eye Disease (DED) and Immunity: A Randomized Controlled Trial 2024 · intervention group · Adults aged 18 years or older with dry eye symptoms | 6 mg | 20 days | — |
| Effects of lutein and lycopene on carotid intima-media thickness in Chinese subjects with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial 2014 · 20 mg lutein/d · Chinese adults aged 45–68 with subclinical atherosclerosis | 20 mg | 1 year | 48 |
| Lutein supplementation over a one-year period in early AMD might have a mild beneficial effect on visual acuity: the CLEAR study 2013 · L group · Adults with early age-related macular degeneration; mean age 70.5 years; sex not reported | 10 mg | 1 year | 36 |
| The effect of lutein supplementation on blood plasma levels of complement factor D, C5a and C3d 2013 · lutein · Men and women aged 50–80 with early signs of age-related macular degeneration | 10 mg | 1 year | 35 |
| Clinical Effects of Dietary Supplementation of Lutein with High Bio-Accessibility on Macular Pigment Optical Density and Contrast Sensitivity: A Randomized Double-Blind Placebo-Controlled Parallel-Group Comparison Trial 2020 · lutein group · Healthy adult men and women aged 20–69 years | 12 mg | 16 weeks | 31 |
| Effect of lutein and zeaxanthin on macular pigment and visual function in patients with early age-related macular degeneration 2012 · 10 mg/day lutein · Adults aged 50–79 with early age-related macular degeneration | 10 mg | 48 weeks | 27 |
| Effect of lutein and zeaxanthin on macular pigment and visual function in patients with early age-related macular degeneration 2012 · 20 mg/day lutein · Adults aged 50–79 with early age-related macular degeneration | 20 mg | 48 weeks | 27 |
| Supplementation with lutein or lutein plus green tea extracts does not change oxidative stress in adequately nourished older adults 2010 · lutein group · Men and postmenopausal women aged 50–70 years in good health | 12 mg | 16 weeks | 20 |
| Epilutein for Early-Stage Age-Related Macular Degeneration: A Randomized and Prospective Study 2017 · group 2 · Adults with early-stage age-related macular degeneration; mean age 72.0 years; sex not reported | 10 mg | 60 days | 16 |
| Efficacy of lutein supplements on macular pigment optical density in highly myopic individuals: A randomized controlled trial 2023 · lutein group · Adults aged 20–50 years with high myopia (axial length 26.5 mm to less than 30.0 mm) | 20 mg | 26 weeks | 15 |
| Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial) 2004 · Group 1 (L) · Patients with atrophic age-related macular degeneration; age and sex not specified | 10 mg | 1 year | — |
| Modification of lymphocyte DNA damage by carotenoid supplementation in postmenopausal women 2006 · lutein · Healthy, nonsmoking postmenopausal women aged 50–70 years | 12 mg | 8 weeks | — |
| LAST II: Differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls 2007 · group 1 · patients with atrophic age-related macular degeneration; age and sex not specified | 10 mg | 1 year | — |
| Lutein supplementation leads to decreased soluble complement membrane attack complex sC5b-9 plasma levels 2015 · lutein group · Elderly patients with signs of early age-related macular degeneration (AMD) | 10 mg | 1 year | — |
| Changes following supplementation with lutein and zeaxanthin in retinal function in eyes with early age-related macular degeneration: a randomised, double-blind, placebo-controlled trial 2015 · 10 mg lutein · Patients with early age-related macular degeneration | 10 mg | 2 years | — |
| Changes following supplementation with lutein and zeaxanthin in retinal function in eyes with early age-related macular degeneration: a randomised, double-blind, placebo-controlled trial 2015 · 20 mg lutein · Patients with early age-related macular degeneration | 20 mg | 2 years | — |
| Oral Lutein Supplementation Enhances Macular Pigment Density and Contrast Sensitivity but Not in Combination With Polyunsaturated Fatty Acids 2015 · lutein and antioxidant supplement · Patients with age-related maculopathy | 10 mg | 26 weeks | — |
| Effect of lutein supplementation on blood lipids and advanced glycation end products in adults with central obesity: a double-blind randomized controlled trial 2025 · lutein supplementation group · Adults with central obesity; age and sex not specified | 10 mg | 32 weeks | — |
| Amount of fat in the diet affects bioavailability of lutein esters but not of alpha-carotene, beta-carotene, and vitamin E in humans 2000 · lutein esters group · Volunteers; age, sex, and health status not specified | 8 mg | 2 weeks | — |
| Dose-ranging study of lutein supplementation in persons aged 60 years or older 2006 · 5-mg lutein group · Adults aged 60 years or older, with no AMD, large drusen, or advanced AMD | 5 mg | 26 weeks | — |
| Lutein bioavailability from lutein ester-fortified fermented milk: in vivo and in vitro study 2010 · High-fortification fermented milk · Volunteers; age, sex, and health status not specified | 8 mg | 2 weeks | — |
| Serum lutein and its dynamic changes during supplementation with lutein in Chinese subjects 2009 · 6 mg lutein/d group · Healthy Chinese subjects; age and sex range not specified | 6 mg | 12 weeks | — |
| Serum lutein response is greater from free lutein than from esterified lutein during 4 weeks of supplementation in healthy adults 2010 · lutein esters (Le) group · Adults aged 23–52 years with baseline serum lutein below 20 µg/dL and BMI above 20 and below 30 kg/m² | 27 mg | 4 weeks | — |
| Effect of Lutein Ester Supplement on Choroidal Thickness in Children: A Randomized Controlled Trial 2025 · Treatment group · Children aged 8–12 years, including children with normal vision and poor vision | 8 mg | 26 weeks | 90 |
| Effects of lutein and lycopene on carotid intima-media thickness in Chinese subjects with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial 2014 · 20 mg lutein/d+20 mg lycopene/d · Chinese adults aged 45–68 with subclinical atherosclerosis | 20 mg | 1 year | 48 |
| Effects of Lutein Supplementation in Japanese Patients with Unilateral Age-Related Macular Degeneration: The Sakai Lutein Study 2020 · Beeswax capsule group · Adults with unilateral exudative age-related macular degeneration; mean age 69.5 years, 13 men and 7 women | 20 mg | 26 weeks | 20 |
| Effects of Lutein Supplementation in Japanese Patients with Unilateral Age-Related Macular Degeneration: The Sakai Lutein Study 2020 · Glycerol fatty acid esters capsule group · Adults with unilateral exudative age-related macular degeneration; mean age 72.0 years, 11 men and 8 women | 20 mg | 26 weeks | 19 |
| Randomized, double-blind, placebo-controlled study of zeaxanthin and visual function in patients with atrophic age-related macular degeneration: the Zeaxanthin and Visual Function Study (ZVF) FDA IND #78, 973 2011 · 9 mg L ("Faux Placebo," control group) · Patients with mild-to-moderate age-related macular degeneration, mean age 74.9 years; 57 men and 3 women across the study | 9 mg | 1 year | 10 |
| Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial) 2004 · Group 2 (L/A) · Patients with atrophic age-related macular degeneration; age and sex not specified | 10 mg | 1 year | — |
| LAST II: Differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls 2007 · group 2 · patients with atrophic age-related macular degeneration; age and sex not specified | 10 mg | 1 year | — |
| Lutein and beta-carotene from lutein-containing yellow carrots are bioavailable in humans 2004 · lutein supplement (LS treatment) · Women and men aged 23–28; no condition reported | 1.7 mg | 7 days | 9 |
| Dose-ranging study of lutein supplementation in persons aged 60 years or older 2006 · 2.5-mg lutein group · Adults aged 60 years or older, with no AMD, large drusen, or advanced AMD | 2.5 mg | 26 weeks | — |
| Effect of Spinacia oleraceae L. and Perilla frutescens L. on antioxidants and lipid peroxidation in an intervention study in healthy individuals 2010 · Spinach preparation · Healthy volunteers; age and sex not reported | 5 mg | 10 days | — |
| Effect of Spinacia oleraceae L. and Perilla frutescens L. on antioxidants and lipid peroxidation in an intervention study in healthy individuals 2010 · Perilla preparation · Healthy volunteers; age and sex not reported | 5 mg | 10 days | — |
| Effects of lutein and docosahexaenoic Acid supplementation on macular pigment optical density in a randomized controlled trial 2013 · intervention group · Adults with early age-related macular degeneration; mean age 69.2 years, both sexes | 12 mg | 1 year | 23 |
| A double-blind, placebo-controlled study on the effects of lutein and zeaxanthin on photostress recovery, glare disability, and chromatic contrast 2014 · L+Z · Young, healthy subjects; age and sex not specified | 10 mg | 1 year | 57 |
| A double-blind, placebo-controlled study on the effects of lutein and zeaxanthin on neural processing speed and efficiency 2014 · Multi · Healthy adults aged 18–32 years | 8 mg | 120 days | 25 |
| Night Vision and Carotenoids (NVC): A Randomized Placebo Controlled Clinical Trial on Effects of Carotenoid Supplementation on Night Vision in Older Adults 2021 · treatment group · Older US veterans with difficulty seeing at night, without overt ocular disease; mean age 62.7 years | 7 mg | 26 weeks | 24 |
| Bioavailability of Lutein from Marigold Flowers (Free vs. Ester Forms): A Randomised Cross-Over Study to Assess Serum Response and Visual Contrast Threshold in Adults 2024 · Free lutein · Apparently healthy men and women aged 20–35 and 50–65 years | 6 mg | 60 days | 24 |
| Bioavailability of Lutein from Marigold Flowers (Free vs. Ester Forms): A Randomised Cross-Over Study to Assess Serum Response and Visual Contrast Threshold in Adults 2024 · Lutein ester · Apparently healthy men and women aged 20–35 and 50–65 years | 6 mg | 60 days | 24 |
| The effect of modified eggs and an egg-yolk based beverage on serum lutein and zeaxanthin concentrations and macular pigment optical density: results from a randomized trial 2014 · Lutein Egg · Healthy adults aged 18 years and older with macular pigment optical density below 0.55 | 921 mcg | 90 days | 20 |
| The effect of modified eggs and an egg-yolk based beverage on serum lutein and zeaxanthin concentrations and macular pigment optical density: results from a randomized trial 2014 · Zeaxanthin Egg · Healthy adults aged 18 years and older with macular pigment optical density below 0.55 | 174 mcg | 90 days | 20 |
| Macular carotenoid supplementation in subjects with atypical spatial profiles of macular pigment 2012 · Group 1 · Healthy subjects with atypical macular pigment spatial profiles; age and sex not stated | 20 mg | 8 weeks | 10 |
| Macular carotenoid supplementation in subjects with atypical spatial profiles of macular pigment 2012 · Group 2 · Healthy subjects with atypical macular pigment spatial profiles; age and sex not stated | 10 mg | 8 weeks | 10 |
| Macular carotenoid supplementation in subjects with atypical spatial profiles of macular pigment 2012 · Group 3 · Healthy subjects with atypical macular pigment spatial profiles; age and sex not stated | 3 mg | 8 weeks | 10 |
| Plasma kinetics of lutein, zeaxanthin, and 3-dehydro-lutein after multiple oral doses of a lutein supplement 2005 · group 1 · healthy volunteers | 4.1 mg | 6 weeks | 8 |
| Plasma kinetics of lutein, zeaxanthin, and 3-dehydro-lutein after multiple oral doses of a lutein supplement 2005 · group 2 · healthy volunteers | 20.5 mg | 6 weeks | 8 |
| Effect of the main dietary antioxidants (carotenoids, gamma-tocopherol, polyphenols, and vitamin C) on alpha-tocopherol absorption 2007 · Meal containing 18 mg lutein · Healthy men; age not reported | 18 mg | 1 day | 8 |
| Effect of the main dietary antioxidants (carotenoids, gamma-tocopherol, polyphenols, and vitamin C) on alpha-tocopherol absorption 2007 · Meal containing 36 mg lutein · Healthy men; age not reported | 36 mg | 1 day | 8 |
| The effect of lutein and zeaxanthin supplementation on metabolites of these carotenoids in the serum of persons aged 60 or older 2006 · 2.5 mg/d lutein group · Adults aged 60 or older, with or without age-related macular degeneration | 2.5 mg | 180 days | — |
| The effect of lutein and zeaxanthin supplementation on metabolites of these carotenoids in the serum of persons aged 60 or older 2006 · 5.0 mg/d lutein group · Adults aged 60 or older, with or without age-related macular degeneration | 5 mg | 180 days | — |
| The effect of lutein and zeaxanthin supplementation on metabolites of these carotenoids in the serum of persons aged 60 or older 2006 · 10 mg/d lutein group · Adults aged 60 or older, with or without age-related macular degeneration | 10 mg | 180 days | — |
| The influence of supplemental lutein and docosahexaenoic acid on serum, lipoproteins, and macular pigmentation 2008 · lutein + DHA · Women aged 60–80 years | 12 mg | 120 days | — |
| Serum response to supplemental macular carotenoids in subjects with and without age-related macular degeneration 2013 · Group 1 · Adults with or without age-related macular degeneration; age and sex not reported | 20 mg | 8 weeks | — |
| Serum response to supplemental macular carotenoids in subjects with and without age-related macular degeneration 2013 · Group 2 · Adults with or without age-related macular degeneration; age and sex not reported | 10 mg | 8 weeks | — |
| Serum response to supplemental macular carotenoids in subjects with and without age-related macular degeneration 2013 · Group 3 · Adults with or without age-related macular degeneration; age and sex not reported | 3 mg | 8 weeks | — |
| Serum and macular responses to multiple xanthophyll supplements in patients with early age-related macular degeneration 2013 · lutein plus zeaxanthin (LZ) · Chinese patients older than 50 years with early age-related macular degeneration | 10 mg | 48 weeks | — |
| Age-related macular degeneration: Effects of a short-term intervention with an oleaginous kale extract--a pilot study 2013 · kale group · Adults with non-exudative age-related macular degeneration; age range and sex not reported | 10 mg | 4 weeks | — |
| Effect of Long-Term Xanthophyll and Anthocyanin Supplementation on Lutein and Zeaxanthin Serum Concentrations and Macular Pigment Optical Density in Postmenopausal Women 2018 · Group X—xanthophylls · Postmenopausal women aged 50–70 years | 6 mg | 240 days | — |
| Effect of Long-Term Xanthophyll and Anthocyanin Supplementation on Lutein and Zeaxanthin Serum Concentrations and Macular Pigment Optical Density in Postmenopausal Women 2018 · Group X+A—anthocyanines and xanthophylls · Postmenopausal women aged 50–70 years | 6 mg | 240 days | — |
| Systemic Effects of Prenatal Carotenoid Supplementation in the Mother and her Child: The Lutein and Zeaxanthin in Pregnancy (L-ZIP) Randomized Trial -Report Number 1 2023 · Carotenoid group · First-trimester pregnant subjects | 10 mg | 240 days | — |
| Supplementation With Carotenoids, Omega-3 Fatty Acids, and Vitamin E Has a Positive Effect on the Symptoms and Progression of Alzheimer's Disease 2022 · active group · People with mild-moderate Alzheimer's disease; age and sex not reported | 10 mg | 1 year | 50 |
| Lutein and Zeaxanthin Supplementation Improves Dynamic Visual and Cognitive Performance in Children: A Randomized, Double-Blind, Parallel, Placebo-Controlled Study 2024 · LZ group · Children aged 5–12 years, male and female | 10 mg | 180 days | 40 |
| Spread supplemented with moderate doses of vitamin E and carotenoids reduces lipid peroxidation in healthy, nonsmoking adults 2003 · spread A · healthy adults | 450 mcg | 11 weeks | 35 |
| Spread supplemented with moderate doses of vitamin E and carotenoids reduces lipid peroxidation in healthy, nonsmoking adults 2003 · spread B · healthy adults | 1.24 mg | 11 weeks | 35 |
| Lutein supplementation increases breast milk and plasma lutein concentrations in lactating women and infant plasma concentrations but does not affect other carotenoids 2014 · low-dose group · Women aged 18 years or older, 4–6 weeks postpartum, continuously lactating and breastfeeding full-term singleton infants | 6 mg | 6 weeks | 29 |
| Effect of lutein and zeaxanthin on macular pigment and visual function in patients with early age-related macular degeneration 2012 · 10 mg/day lutein plus 10 mg/day zeaxanthin · Adults aged 50–79 with early age-related macular degeneration | 10 mg | 48 weeks | 27 |
| Lutein supplementation increases breast milk and plasma lutein concentrations in lactating women and infant plasma concentrations but does not affect other carotenoids 2014 · high-dose group · Women aged 18 years or older, 4–6 weeks postpartum, continuously lactating and breastfeeding full-term singleton infants | 12 mg | 6 weeks | 26 |
| Randomized, double-blind, placebo-controlled study of zeaxanthin and visual function in patients with atrophic age-related macular degeneration: the Zeaxanthin and Visual Function Study (ZVF) FDA IND #78, 973 2011 · 8 mg Zx plus 9 mg lutein · Patients with mild-to-moderate age-related macular degeneration, mean age 74.9 years; 57 men and 3 women across the study | 9 mg | 1 year | 25 |
| Supplementation with three different macular carotenoid formulations in patients with early age-related macular degeneration 2014 · Group 2 · People with early age-related macular degeneration; age and sex not stated | 10 mg | 1 year | 21 |
| Epilutein for Early-Stage Age-Related Macular Degeneration: A Randomized and Prospective Study 2017 · group 1 · Adults with early-stage age-related macular degeneration; mean age 69.4 years; sex not reported | 2 mg | 60 days | 21 |
| Supplementation with lutein or lutein plus green tea extracts does not change oxidative stress in adequately nourished older adults 2010 · lutein plus green tea extract group · Men and postmenopausal women aged 50–70 years in good health | 12 mg | 16 weeks | 20 |
| Changes in Macular Pigment Optical Density and Serum Lutein Concentration in Japanese Subjects Taking Two Different Lutein Supplements 2015 · FloraGLO group · Healthy Japanese adults aged 20 years and older, without ocular or systemic pathologies | 10.5 mg | 26 weeks | 18 |
| Changes in Macular Pigment Optical Density and Serum Lutein Concentration in Japanese Subjects Taking Two Different Lutein Supplements 2015 · XanMax group · Healthy Japanese adults aged 20 years and older, without ocular or systemic pathologies | 10.4 mg | 26 weeks | 18 |
| Supplementation with three different macular carotenoid formulations in patients with early age-related macular degeneration 2014 · Group 1 · People with early age-related macular degeneration; age and sex not stated | 20 mg | 1 year | 17 |
| Goji Berry Intake Increases Macular Pigment Optical Density in Healthy Adults: A Randomized Pilot Trial 2021 · LZ supplement group · Healthy men and women aged 45–65 years with normal macular condition and no signs of drusen or early AMD | 6 mg | 90 days | 15 |
| Supplementation with three different macular carotenoid formulations in patients with early age-related macular degeneration 2014 · Group 3 · People with early age-related macular degeneration; age and sex not stated | 3 mg | 1 year | 14 |
| Modification of lymphocyte DNA damage by carotenoid supplementation in postmenopausal women 2006 · mixed carotenoids · Healthy, nonsmoking postmenopausal women aged 50–70 years | 4 mg | 8 weeks | — |
| Supplementation with all three macular carotenoids: response, stability, and safety 2011 · intervention (I group) · healthy adults; age and sex not specified | 5.9 mg | 26 weeks | — |
| The impact of macular pigment augmentation on visual performance using different carotenoid formulations 2012 · group 1 · Adults, 19–64 years (mean age 51 years), 19 male and 17 female across the study; condition not specified | 20 mg | 26 weeks | — |
| The impact of macular pigment augmentation on visual performance using different carotenoid formulations 2012 · group 2 · Adults, 19–64 years (mean age 51 years), 19 male and 17 female across the study; condition not specified | 10 mg | 26 weeks | — |
| Macular xanthophylls and ω-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial 2013 · group 1 · Individuals with nonexudative age-related macular degeneration; age and sex not specified | 10 mg | 1 year | — |
| Changes following supplementation with lutein and zeaxanthin in retinal function in eyes with early age-related macular degeneration: a randomised, double-blind, placebo-controlled trial 2015 · lutein (10 mg)+zeaxanthin (10 mg) · Patients with early age-related macular degeneration | 10 mg | 2 years | — |
| The impact of supplemental macular carotenoids in Alzheimer's disease: a randomized clinical trial 2015 · Macushield, Alzheimer's disease patients · Adults with Alzheimer's disease; age range and sex not stated | 10 mg | 26 weeks | — |
| The impact of supplemental macular carotenoids in Alzheimer's disease: a randomized clinical trial 2015 · Macushield, age-similar control subjects · Age-similar control subjects; age range and sex not stated | 10 mg | 26 weeks | — |
| Sustained supplementation and monitored response with differing carotenoid formulations in early age-related macular degeneration 2015 · Group 1 · People with early age-related macular degeneration; age and sex not specified | 20 mg | 3 years | — |
| Sustained supplementation and monitored response with differing carotenoid formulations in early age-related macular degeneration 2015 · Group 2 · People with early age-related macular degeneration; age and sex not specified | 10 mg | 3 years | — |
| Sustained supplementation and monitored response with differing carotenoid formulations in early age-related macular degeneration 2015 · Group 3 · People with early age-related macular degeneration; age and sex not specified | 3 mg | 3 years | — |
| Oral Lutein Supplementation Enhances Macular Pigment Density and Contrast Sensitivity but Not in Combination With Polyunsaturated Fatty Acids 2015 · lutein and antioxidant supplement in combination with PUFA · Patients with age-related maculopathy | 10 mg | 26 weeks | — |
| The effects of lutein and zeaxanthin on resting state functional connectivity in older Caucasian adults: a randomized controlled trial 2020 · Lutein and zeaxanthin supplement · Community-dwelling older adults, mean age 72 years | 10 mg | 1 year | — |
| Lack of a Synergistic Effect on Cardiometabolic and Redox Markers in a Dietary Supplementation with Anthocyanins and Xanthophylls in Postmenopausal Women 2019 · Group X (xanthophylls) · Women aged 50–70 years, postmenopausal for more than two years, with BMI 25–33 kg/m² | 6 mg | 243 days | — |
| Lack of a Synergistic Effect on Cardiometabolic and Redox Markers in a Dietary Supplementation with Anthocyanins and Xanthophylls in Postmenopausal Women 2019 · Group A+X (anthocyanins + xanthophylls) · Women aged 50–70 years, postmenopausal for more than two years, with BMI 25–33 kg/m² | 6 mg | 243 days | — |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS2 lutein plus zeaxanthin · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye | 10 mg | 5 years | — |
| Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study 2013 · D2 (twice daily) · Patients with non-exudative age-related macular degeneration; age and sex not specified | 20 mg | 1 year | 55 |
| Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study 2013 · D1 (once daily) · Patients with non-exudative age-related macular degeneration; age and sex not specified | 10 mg | 1 year | 50 |
| [Metabolic estimation of efficiency of vitamin and mineral complexes in qualified athletes] 2021 · main group · Professional athletes in cyclic sports; age and sex not stated | 4.5 mg | 30 days | 42 |
| Dietary supplementation with a natural carotenoid mixture decreases oxidative stress 2003 · Fish oil plus natural carotenoid mixture · Healthy, free-living, nonsmoking adults | 4.4 mg | 3 weeks | 31 |
| Consumption of Hen Eggs Enriched with n-3 Polyunsaturated Fatty Acids, Selenium, Vitamin E and Lutein Incites Anti-Inflammatory Conditions in Young, Healthy Participants - A Randomized Study 2022 · 4Nutri group · Young, healthy participants; age range and sex not stated | 1.85 mg | 3 weeks | 20 |
| Lutein Complex Supplementation Increases Ocular Blood Flow Biomarkers in Healthy Subjects 2019 · lutein phytochemicals complex · Healthy women, mean age 36.8 ± 12.1 years | 10 mg | 3 weeks | 16 |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS2 lutein/zeaxanthin plus DHA/EPA · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye | 10 mg | 5 years | — |